Please assess the completion status of the following clinical trial:

Trial Title: SWOG-9346, Hormone Therapy in Treating Men With Stage IV Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed adenocarcinoma of the prostate~  * Metastatic stage IV (stage D2)~    * Any number of bone metastases by bone scan allowed~   * Unequivocal visceral organ metastases (liver, brain, or lung) allowed~ * No suspected second primary tumors unless metastases are histologically confirmed, including special stains (e.g., prostate specific antigen \[PSA\] and prostatic alkaline phosphatase \[PAP\])~* For entry into late induction therapy:~  * No more than 1 month from the beginning of antiandrogen therapy to the beginning of luteinizing hormone-releasing hormone (LHRH) agonist therapy~ * No more than 6 months since initiation of current combined androgen-deprivation therapy (LHRH agonist and antiandrogen)~ * The effectiveness of the current depot LHRH agonist would not extend beyond 8 months after initiation of combined androgen therapy~* PSA at least 5 ng/mL~* No acute spinal cord compression~PATIENT CHARACTERISTICS:~Age:~* Adult~Performance status:~* SWOG 0-2~Hematopoietic:~* Not specified~Hepatic:~* Not specified~Renal:~* Not specified~Other:~* Recovered from any major infection~* No active medical illness that would preclude study or limit survival~* No other malignancy within the past 5 years except:~  * Adequately treated basal cell or squamous cell skin cancer~ * Adequately treated carcinoma in situ of the bladder~ * Adequately treated other superficial cancer~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* No concurrent biological response modifier therapy~Chemotherapy:~* No concurrent chemotherapy~Endocrine therapy:~* See Disease Characteristics~* More than 1 year since any prior neoadjuvant or adjuvant hormonal therapy for a duration of no more than 4 months~  * Single or combination therapy allowed~* More than 1 year since prior finasteride for prostate cancer for a duration of no more than 9 months (less than 6 months for benign prostatic hypertrophy)~* Prior or concurrent megestrol for hot flashes allowed~* No other concurrent hormonal therapy~Radiotherapy:~* No concurrent radiotherapy other than palliation of painful bone metastases~Surgery:~* No prior bilateral orchiectomy~* Recovered from any prior major surgery

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Consolidation arm I (Type: ACTIVE_COMPARATOR): Patients continue CAD therapy comprising goserelin subcutaneously once a month and oral bicalutamide once daily. Treatment continues in the absence of disease progression.
- Consolidation arm II (Type: EXPERIMENTAL): Patients undergo observation in the absence of rising prostate-specific antigen (PSA) or clinical symptoms of progressive disease. Patients with rising PSA or progressive disease begin CAD therapy as in consolidation arm I. Patients whose PSA normalizes after 8 courses return to observation. Patients whose PSA does not normalize after 8 courses continue CAD therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).